TerminatedNCT07329621

A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults

Medication studyAges 23–55United KingdomDepression

The study in practice

Understand this study

Listed age limits: 23 years to 55 years.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: January 15, 2026

Recruitment status: Terminated
Enrollment listed in the registry: 8
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United Kingdom
Age range: From 23 Years to 55 Years
Official registry ID: NCT07329621
Official title: Show the full official title
A Phase 1, Open-label, Positron Emission Tomography (PET) Trial to Measure Serotonin 5-HT2A Receptor Occupancy Following Single Oral Doses of MSP-2020 in Healthy Male Adults

Terminated

London

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including MSP-2020.

Who can participate?

Listed age limits: 23 years to 55 years.

Is this study still recruiting?

The registry lists this study as terminated.